JP2025508779A5 - - Google Patents
Info
- Publication number
- JP2025508779A5 JP2025508779A5 JP2024549466A JP2024549466A JP2025508779A5 JP 2025508779 A5 JP2025508779 A5 JP 2025508779A5 JP 2024549466 A JP2024549466 A JP 2024549466A JP 2024549466 A JP2024549466 A JP 2024549466A JP 2025508779 A5 JP2025508779 A5 JP 2025508779A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210172397 | 2022-02-24 | ||
| CN202210172397.7 | 2022-02-24 | ||
| CN202210916833.7 | 2022-08-01 | ||
| CN202210916833 | 2022-08-01 | ||
| CN202211183393 | 2022-09-27 | ||
| CN202211183393.5 | 2022-09-27 | ||
| PCT/CN2023/078127 WO2023160651A1 (zh) | 2022-02-24 | 2023-02-24 | 一种抗体及其药物偶联物和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508779A JP2025508779A (ja) | 2025-04-10 |
| JP2025508779A5 true JP2025508779A5 (https=) | 2026-03-02 |
| JPWO2023160651A5 JPWO2023160651A5 (https=) | 2026-03-02 |
Family
ID=87764835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024549466A Pending JP2025508779A (ja) | 2022-02-24 | 2023-02-24 | 抗体及びその薬物コンジュゲート並びに用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250333541A1 (https=) |
| EP (1) | EP4484446A1 (https=) |
| JP (1) | JP2025508779A (https=) |
| KR (1) | KR20240150773A (https=) |
| CN (1) | CN118786146A (https=) |
| AU (1) | AU2023225240A1 (https=) |
| CA (1) | CA3244292A1 (https=) |
| WO (1) | WO2023160651A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202543685A (zh) * | 2024-03-04 | 2025-11-16 | 大陸商蘇州宜聯生物醫藥有限公司 | 抗體藥物偶聯物及其製備方法和用途 |
| TW202600596A (zh) * | 2024-03-04 | 2026-01-01 | 大陸商杭州中美華東製藥有限公司 | 抗ＦＧＦＲ２ｂ抗體、其抗體藥物偶聯物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| MX2020005473A (es) * | 2017-11-27 | 2020-08-27 | Purdue Pharma Lp | Anticuerpos humanizados que se dirigen al factor tisular humano. |
| CA3094313A1 (en) | 2018-04-06 | 2019-10-10 | Seattle Genetics, Inc. | Camptothecin peptide conjugates |
| CN110575547B (zh) * | 2018-06-07 | 2021-07-30 | 中国科学院上海药物研究所 | 靶向于tf的抗体-药物偶联物及其制法和用途 |
| MX2021015974A (es) * | 2019-07-03 | 2022-04-26 | Iconic Therapeutics Inc | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados. |
| MX2023000499A (es) * | 2020-07-10 | 2023-04-20 | Iconic Therapeutics Inc | Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular. |
| MX2023001163A (es) * | 2020-07-27 | 2023-02-22 | Tuojie Biotech Shanghai Co Ltd | Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo. |
| MX2023008895A (es) | 2021-02-09 | 2023-08-09 | Medilink Therapeutics Suzhou Co Ltd | Conjugado de sustancia bioactiva, metodo de preparacion y uso del mismo. |
-
2023
- 2023-02-24 AU AU2023225240A patent/AU2023225240A1/en active Pending
- 2023-02-24 CA CA3244292A patent/CA3244292A1/en active Pending
- 2023-02-24 WO PCT/CN2023/078127 patent/WO2023160651A1/zh not_active Ceased
- 2023-02-24 CN CN202380023138.0A patent/CN118786146A/zh active Pending
- 2023-02-24 JP JP2024549466A patent/JP2025508779A/ja active Pending
- 2023-02-24 US US18/841,222 patent/US20250333541A1/en active Pending
- 2023-02-24 EP EP23759273.8A patent/EP4484446A1/en active Pending
- 2023-02-24 KR KR1020247029450A patent/KR20240150773A/ko active Pending